Management of Aromatase Inhibitor-Induced Musculoskeletal Symptoms.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32780640.
- Also identified by DOI 10.1200/OP.20.00113.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) were first recognized as a distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole. Musculoskeletal symptoms can severely affect patients' quality of life and also lead to premature discontinuation of aromatase inhibitor therapy. Several interventions for managing AIMSS have been investigated in the last decade, with some demonstrating promise. This article provides an evidence-based summary to guide practicing oncologists in regard to the epidemiology, prevention, and treatment of AIMSS.
Medical subject headings
- Aromatase Inhibitors
- Quality of Life